Phase 1/2RecruitingNCT06524960
Denosumab for beta-cell function in T1D
Phase 1/2 trial testing whether the RANKL inhibitor denosumab can improve beta-cell function and glycemic control in early T1D.
Primary endpoints
- Primary safety endpoint
- Primary efficacy endpoint
Results so far
No results posted yet.